European CHMP recommends license extension of nivolumab (Opdivo) as first-line treatment for advanced renal cell carcinoma

The proposed license extension is in combination with cabozantinib for the first-line treatment of adult patients with advanced renal cell carcinoma.

Source:

European Medicines Agency